Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers

@article{Mansouri1999SafetyAI,
  title={Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers},
  author={E. Mansouri and J. Gabelsberger and B. Knapp and E. Hundt and U. Lenz and K. Hungerer and H. E. Gilleland and J. Staczek and H. Domdey and B. V. von Specht},
  journal={Infection and Immunity},
  year={1999},
  volume={67},
  pages={1461 - 1470}
}
ABSTRACT A hybrid protein [Met-Ala-(His)6OprF190–342-OprI21–83] consisting of the mature outer membrane protein I (OprI) and amino acids 190 to 342 of OprF of Pseudomonas aeruginosa was expressed in Escherichia coli and purified by Ni2+ chelate-affinity chromatography. After safety and pyrogenicity evaluations in animals, four groups of eight adult human volunteers were vaccinated intramuscularly three times at 4-week intervals and revaccinated 6 months later with either 500, 100, 50, or 20 μg… Expand
Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa.
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Potential of protein OprF of Pseudomonas in bivalent vaccines.
Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
  • G. Pier
  • Biology, Medicine
  • The Journal of clinical investigation
  • 1982
Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay.
...
1
2
3
4
5
...